Study on Intraocular Pressure After Aflibercept 0.07mL Injection
The AFLIPIO study will evaluate the intraocular pressure effects and anatomical repercussions of Aflibercept 0.07mL injections over 12 months.
Phase III
retinal disease treatment protocols
Status
Active
Sponsor
Anti-VEGF
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The AFLIPIO study is critical as it evaluates the intraocular pressure effects of a higher volume Aflibercept injection, which may lead to significant changes in treatment protocols for retinal diseases. Understanding these implications is vital for ensuring patient safety and optimizing therapeutic strategies in ophthalmology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor outcomes of the AFLIPIO study, particularly regarding intraocular pressure spikes and long-term optic nerve health.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.